We describe the case of an elderly female who had received IV bisphosphonates (Zoledronic acid) and had presented with a non healing tooth socket after tooth removal. The patient was managed conservatively with local curettage and recovered from the jaw problem.
INTRODUCTION
The purpose of this case report is to increase awareness about the worldwide growing problem of Bisphosphonate Associated Osteonecrosis of the Jaws (BRONJ) and a case is presented in this regard.
Bisphosphonates are pharmacological agents which are used in the treatment of osteoporosis and malignant bone metastases. The intravenous and oral forms of administration differ in their potency and indications; while the intravenous forms (Pamidronate and Zoledronate) are used in a select patient population especially for treatment of multiple myeloma and metastatic breast cancer deposits, the oral forms (e.g. Etidronate, Alendronate and Risedronate) are used routinely in prevention and treatment of postmenopausal and steroid-induced osteoporosis. Their effectiveness in treatment of hypercalcemia of malignancy and osteoporosis stems from their ability to inhibit osteoclast function and as a result, affecting bone turnover [1] . Once administered systemically, bisphosphonates bind irreversibly with bone due to their central carbon atom and are internalized by osteoclasts and affect osteoclast mediated bone resorption. This happens through impairment of function and apoptotic cell death of osteoclasts and osteoclast precursors in the bone marrow [2, 3] .
Since bone deposition and bone turnover are processes inherently linked to bone resorption, any interference with bone resorption logically triggers disturbance of normal physiologic function of bone and *Address correspondence to this author at the Department of Dental Diagnostic & Surgical Sciences, University of Manitoba, Winnipeg, Canada; Tel: +1 204 789 3338; Fax: +1 204 272 3077; E-mail: adnanshahsyed@gmail.com its ability to repair itself in case of injury or stresses as a result of functional loading [4] . As a consequence of normal osteoclastic bone resorption, the secretion of various chemicals like BMP (Bone morphogeneic protein), ILG -1 and ILG-2 (Insulin-like growth factor) leads to bone deposition and renewal of the aging osteocytes [5, 6] . However, in the setting of hampered osteoclastic resorption of bone as a result of bisphosphonate administration, the aging osteocytes are not resorbed and replaced, and after hyermineralization and sclerosis, the bone becomes brittle and fracture prone or undergoes necrosis [7] [8] [9] .
Two pioneering reports made oral and maxillofacial surgeons the first clinicians to report a disturbing sequel to bisphosphonate treatment, when Marx in 2003 [10] and Ruggiero [11] reported their respective series of patients on bisphosphonate therapy who had developed osteonecrosis of the jaws. This event was seen to be a spontaneous response to intravenous bisphosphonate therapy in some individuals and mostly, a result of dentoalveolar surgery. This was followed by many other reports which led the relevant drug manufacturers to label these IV products with a precautionary warning related to the development of osteonecrosis of the jaws, and later a wider bisphosphonate warning, encompassing the oral preparations too.
CASE REPORT
A 65 years old female patient was referred to the oral and maxillofacial surgery service with the presenting complaint of severe pain in left sided lower jaw, foul smell from mouth and occasional pus discharge from the mouth. History of presenting illness revealed that an attempt was made to extract her left mandibular first molar by a local dental practitioner two months back. The tooth could not be removed in one piece and one of the roots was left in situ that was removed surgically later. The wound of the dental extraction and the subsequent surgery never healed and was associated with a notable pus discharge. The medical history was remarkable for a knee replacement surgery in May, 2003 . During the knee replacement surgery she was noted to have breathing problems. Medical workup led to the diagnosis of pericardial effusion and subsequently identification of a breast mass, confirmed histologically as adenocarcinoma. She underwent a mastectomy and axillary lymph node dissection at that time, but the staging confirmed further widespread intra-abdominal lymphadenopathy, but no overt evidence of liver, lung or bone metastasis on nuclear scanning. Following her surgery she was treated with four cycles of platinum and Taxol based chemotherapy followed by six cycles of Doxorubicin and Texotere, with completion of chemotherapy in August, 2004. A series of investigations following chemotherapy, including CT scan of the chest and abdomen, CT of pelvis, mammogram and full body bone scan, confirmed that she was in complete remission with no obvious intra-abdominal disease or substantial lymphadenopathy.
She remained stable till March 2006 when she presented to her oncologist with complaint of severe neck pain. MRI showed a soft tissue mass at C1 and C2 level with significant bone pathology at C1. A chemotherapy regimen was advised that included Bevacizumab (Avastin ®) and Capcitabine (Xeloda®). Xeloda was discontinued after 02 cycles due to severe hand & foot syndrome. Navelbine was introduced along with Avastin, however due to poor IV access Navelbine could not be continued after one cycle. Zoledronic acid (Zometa®) was added with Avastin on four week schedule. Patient was on this regimen for last 16 months. In the first week of August, she presented to our surgical service with the complaint of a non healing dental extraction wound.
At the first time presentation, pus discharge was observed in left posterior mandible with an associated exposed bone through the non healing molar tooth socket with pus expression on slight pressure and was tender to touch (Figure 1) . Review of an OPG ( Figure  2) showed a slight increase in the density of bone in the peri socket area of mandibular first molar, and small radiolucent lytic lesion in the top of interdental bone of first molar socket and just distal to the tooth socket. An incidental finding of a relatively large, well delineated radiolucency was seen, extending from the right sided mandibular first premolar to first molar region. A 2 year old OPG showed this lesion to be constant and stable in size. The associated alveolar region was clinically examined again. The area was asymptomatic, with no clinical expansion, and the associated teeth were found to be non tender to percussion. Small radiolucent lytic lesions in the region of interdental bone of extracted left sided first molar tooth, and also just distal to the dental socket (narrow black arrow). Slight increase in bone density in the peri socket area is also seen. An asymptomatic radiolucency (white thick arrow) in the right mandible is seen. Generalized increases in periodontal spaces can also be observed.
A bone scan was obtained which showed a significantly increased radiotracer uptake in the left mandible; however, the right side did not show any significantly increased radiotracer uptake (Figure 3) .
Considering the recent dental and drug histories, a preliminary diagnosis of BRONJ was established and surgical removal of the involved necrotic bone with a primary closure was planned. Based on the lack of symptoms and stability over two years, a decision was made to adopt a 'wait-and-see' policy towards this radiolucency with a provisional diagnosis of radicular cyst, since given her previous drug history, a surgical exploration could trigger another area of BRONJ. The surgery was done in August, 2007 under GA after discontinuing Zometa for two months. A sequestrectomy of left mandible was done with conservative debridement followed by primary closure (Figures 4, 5 and 6) . In addition to prophylactic antibiotics, the patient was placed on 3 rd generation cephalosporins, clindamycin and metronidazole post operatively. Culture obtained at the start of surgery revealed a predominance of Actinomyces species, which led to continuation of antibiotics for 14 days. Excisional biopsy reported necrotic bone with no evidence of granuloma formation or malignancy. She tolerated the surgery well and was discharged with strict instructions for oral hygiene. No wound dehiscence or infection were observed in the postoperative phase and the wound healed well. Surgical exploration for the asymptomatic radiolucency in the left mandibular body region was offered to the patient, but the patient did not consent for it. It was, however kept under regular follow up, and subsequent imaging showed the size of the radiolucency to be stable. The postoperative course for the surgical site remains uneventful, four years after the surgery (Figures 7 and 8 ). 
DISCUSSION
According to the AAOMS, a working definition of BRONJ has been developed which considers patients to have BRONJ if there is a history of current/previous treatment with a bisphosphonate; exposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks; and with no history of radiation therapy to the jaws [12] . It has been estimated that the cumulative incidence of BRONJ in patients on IV bisphosphonate therapy ranges from 0.8 to 12 % [12]. This is lower in case of oral bisphosphonate therapy with a 0.01 to 0.04 %, which increased to 0.09 to 0.34 % following extractions [12, 13] . It is also estimated while almost 75 % of the BRONJ cases developing from IV use of bisphosphonates are seen following a surgical procedure (with the remaining 25 % developing spontaneously), the cause is more equally distributed between postsurgical or spontaneous development of BRONJ in case of oral bisphosphonate administration [12] . Recent studies have shown a higher risk and incidence of development of BRONJ, in cases of concomitant cytotoxic chemotherapy for active cancer [14] . Marx et al. [15] has recently suggested to have elevated fasting CTX (C-terminal telopeptide) values (when the drug is discontinued) to be a good indicator for either non surgical conservative or surgical treatment. However, this tends to work only in patients on oral bisphosphonates, without active cancer and uncomplicated by concomitant use of drugs like Methotrexate or Prednisone [4] . Patients especially on IV bisphosphonate therapy undergoing oral surgery including uncomplicated exodontia are at an increased risk of development of BRONJ [16] . In our patient, surgical removal of the left sided mandibular first molar probably led to an area of increased bone activity, which failed to heal because the osteoclasts were rendered ineffective by bisphosphonate treatment.
In a case series on patients suffering with BRONJ, all of the patients were seen to have painful ulcerative areas of exposed bone at the site of a previous dental extraction, halitosis, and a persistent purulent discharge; many of the patients also had traumatic mucosal ulcerations in the areas adjacent to the necrotic bone, due to the irregular bony margins [16] . Except for mucosal ulcerations, our patient suffered from all these classic symptoms of BRONJ.
The histopathologic examination of the removed bone in BRONJ reveals a necrotic osteitis associated with the presence of bacteria colonies most commonly Actinomyces species [12] , without evidence of metastatic bone disease, which also excludes it to be a focus of primary or secondary malignant change.
Being a newly discovered entity, the experience with treatment of BRONJ is essentially limited and todate, oral and maxillofacial surgeons have not been able to reach a consensus in devising the most apt treatment. Suggested treatment regimens consist of just taking a drug holiday with no surgical treatment [15] , conservative surgical curettage, surgical resection with some time a continuity defect, with or without vascularized flap reconstruction [17] . However, generally the more aggressive reconstruction procedures are considered more controversial because of an unhealthy tissue bed, not biologically sound to receive transplanted bone. Drug holiday or stopping the drug for 3-9 months is said to be beneficial by many clinicians but according to some, does not have a bearing on the surgical outcome [18] . It is possibly because of the irreversible binding of the drug to bone with a half-life of eleven years, and even on bursting open of the osteoclasts after normal osteoclasts resorbing them, the stored bisphosphonate re enters the systemic circulation in a re dosing effect [4] . Because of the symptoms affecting the daily routine of our patient, it was not possible for us to take a full fledged drug holiday, and the patient was taken off the drug for only two months. On the whole, sequestrectomy with peripheral ostectomy along with a drug holiday is considered to be one of the more appropriate therapies by the majority of the clinicians.
It is also interesting to note that despite being the major oral & maxillofacial surgery centre in the province of Punjab (largest; population wise in Pakistan), this remains todate our only experience with BRONJ, and perhaps the only documented case from Pakistan. This might be due to a difficulty in diagnosis; with BRONJ being a newly discovered entity. A large number of patients with metastatic bone deposits and multiple myeloma are prescribed IV bisphosphonates, which makes us contend that the relatively smaller numbers of BRONJ cases contrary to the experience worldwide might be due to a relative resistance to the drug in our population.
We chose to adhere to a conservative removal of grossly affected bone with attainment of a good, watertight primary closure over the wound, with strict instructions on postoperative oral care. It is expected that other clinicians including general dental practitioners, oral and maxillofacial surgeons and other specialties managing the head and neck will encounter this complication in their practices and therefore, should be aware of the presenting symptoms and management of the condition.
CONCLUSION
IV bisphosphonates form the corner stone of therapy in several patients with lytic bone lesions worldwide. A few of them especially those on a prolonged treatment are at a risk of developing BRONJ, which can be a troublesome complication and difficult to manage. Prevention is the best strategy in management, with care taken in oral surgical procedures in patients, especially on IV bisphosphonates. 
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